Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Dear Editor, Multiple myeloma (MM) is characterized by substantial biological heterogeneity, with outcomes influenced by baseline disease characteristics and depth of response to therapy [1]. Measurable residual disease (MRD) has emerged as a powerful post-treatment prognostic marker; however, assessment of residual disease burden does not directly characterize the proliferative behavior of the remaining clonal plasma cells [2].
Sayeh Fattahi and Daniel G. Packard are co-first authors. This study was presented in part as a proffered paper at the 2026 Annual Congress of the European Society for Radiotherapy and Oncology, Stockholm, Sweden, May 15–19, 2026. Conflicts of Interest T.I.Y. receives in-kind software support from MIM software to support a multicenter pediatric registry and serves on the Scientific Advisory Board for Mevion. N.J.T. chairs the Mevion Medical Advisory Board.
We're excited to launch Spectre3D Studio on Kickstarter, our all-in-one portable 3D scanning studio! This makes 3D scanning easy and enjoyable! Sign up here to get notified when the Kickstarter campaign goes live: https://studio-kickstarter.spectre3d.io/ Spectre3D Studio makes it quick and easy to create professional-quality 3D scans of objects. It's portable, easy to set up, and reduces post processing and cleanup in your completed scans.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
